An Open-Label Sunitinib Malate (SU011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

The objective of the study is to assess long term safety and tolerability of patients enrolling from prior Sutent clinical studies. Duration of clinical benefit will be assessed for patients enrolling from protocol A6181111; PNET.

Outcome Time Frame:

duration of study

Safety Issue:

Yes

Principal Investigator

Pfizer CT.gov Call Center

Investigator Role:

Study Director

Investigator Affiliation:

Pfizer

Authority:

United States: Food and Drug Administration

Study ID:

A6181114

NCT ID:

NCT00428220

Start Date:

July 2007

Completion Date:

May 2014

Related Keywords:

• Metastatic Breast Cancer
• Advanced Breast Cancer
• Advanced Gastric Cancer
• Advanced/Metastatic Non-Small Cell Lung Cancer
• Gastrointestinal Stromal Tumor
• Hepatocellular Carcinoma
• Metastatic Castration-Resistant Prostate Cancer
• Metastatic Renal Cell Cancer
• Non Small Cell Lung Cancer
• Pancreatic Islet Cell Carcinoma
• Pancreatic Neuroendocrine Tumor
• Thyroid Cancer
• Potentially other tumor types in the future
• Breast Neoplasms
• Carcinoma
• Thyroid Neoplasms
• Carcinoma, Non-Small-Cell Lung
• Carcinoma, Renal Cell
• Lung Neoplasms
• Stomach Neoplasms
• Prostatic Neoplasms
• Neuroendocrine Tumors
• Gastrointestinal Stromal Tumors
• Adenoma, Islet Cell
• Carcinoma, Islet Cell
• Carcinoma, Hepatocellular